New York, US–Apr 17, 2019 Recently, Creative Biolabs, a company located in New York, upgraded it customized sequencing service, which comprises de novo monoclonal antibody and hybridoma sequencing services. By improving the service, the company aims to overcome the drawbacks of current sequencing methods, thereby promoting biosimilar development and providing superb sequencing services. This optimized service is expected to benefit its numerous customers around the globe.
It’s of great value to determine the protein sequence of an antibody, in that the sequence enables various downstream applications and developments. First of all, the unique amino acid sequence, particularly that of the variable region, largely dictates the novelty of an antibody. Thereby, the sequence constitutes a key factor in patent application to claim the exclusive rights in downstream antibody development. Then, the antibody sequence matters a great deal to antibody recombinant expression. It acts as a blueprint for vector construction and recombinant expression in various systems. Furthermore, the sequence facilitates antibody downstream development. It serves as a template for various downstream engineering platforms, such as humanization and affinity maturation.
“Acquiring intact and accurate sequence information is critical for the similarity analysis of biosimilar monoclonal antibodies and the development of new biosimilar products. Since the sequence information reported in the literature or patents may differ from that in the market, we need to directly sequence biosimilar monoclonal antibodies. Our service of sequencing monoclonal antibodies takes advantage of Database Assisted Shotgun Sequencing (DASS), the most advanced de novo antibody sequencing technology, and the state-of-the-art AbSeq™ PEAKS Mass Spectrometry Software and Data Processing Algorithm. Therefore, we can guarantee full sequence coverage of biosimilar products with a 100% accuracy rate,” said a scientist from Creative Biolabs.
The other introduced sequencing service is hybridoma sequencing, which means the process of obtaining sequence information about the cDNA encoding the variable heavy (VH) and variable light (VL) domains of the antibody produced by the hybridoma cell line. The hybridoma sequencing service consists of full-length antibody sequencing, V-region sequencing, and recombinant antibody production services.
The same scientist also added that “Our hybridoma sequencing service has many advantages. First, it can be applied to hybridoma cell lines from most rodent species and antibody isotypes. Second, the service can sequence both variable region and full-length antibody proteins. Third, this is a one-stop service, ranging from mRNA extraction, sequence determination, to antibody format conversion. Lastly, the service usually requires a turn-around period of only three weeks.”
The upgraded sequencing service comes with impressive strengths, indeed. Behind this service are top-notch technology, and a team of outstanding scientists with years of experience in the related field. Given the considerable significance of antibody sequencing, more advanced technology may be expected to make the sequencing service better and better, ultimately promoting the development of antibody products.
About Creative Biolabs
Creative Biolabs is a leading custom service provider, boasting rich experience in antibody production and engineering. Its service portfolio includes mouse and rat monoclonal antibody production using hybridoma technology, human, monkey, rabbit, chicken, dog, llama and camel monoclonal antibody production using various antibody library technologies. In addition, the company also conducts in-depth antibody humanization and affinity maturation.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States